Abstract: Disclosed herein are antisense compounds and methods for decreasing alpha-synuclein mRNA and protein expression. Also disclosed herein are methods for treating, preventing, and ameliorating neurodegenerative diseases in an individual in need thereof.
Abstract: Agents and methods for increasing dystrophin protein expression in muscle through blocking of specific microRNAs and microRNA binding sites on the dystrophin 3? untranslated region (miR-146a, miRNA-146b, miR-223, miR-320a, miR374a, and miR-382). Methods for increasing the amount of dystrophin useful for effective therapeutic intervention for Becker muscular dystrophy, Duchenne muscular dystrophy, and other disorders where loss of dystrophin from muscle causes pathology.
Abstract: The present invention relates to microRNAs (miRNAs) which are associated with cancer, particularly including hematologic malignancies, and particularly T-cell acute lymphoblastic leukemia (T-ALL), and to the assessment and modulation thereof in the treatment and management of cancer. The present invention is directed to methods and compositions for diagnosing and treating cancer, particularly T-ALL, by modulating miRNAs, and the use of miRNAs and antagonists thereof, particularly antagomirs, for predicting and assessing response to treatment, in assays for isolating and selecting antagonists, and as compositions for the treatment and management of cancer. Methods and compositions are provided for treatment or alleviation of cancer, particularly T-ALL, with antagonists/antagomirs of miRNAs, particularly one or more of miR-19b, miR-20a, miR26, miR92, miR148 and miR223.
Type:
Grant
Filed:
February 28, 2011
Date of Patent:
April 18, 2017
Assignees:
Memorial Sloan Kettering Cancer Center, Universiteit Gent, Columbia University
Inventors:
Hans-Guido Wendel, Andrew L. Wolfe, Konstantinos John Mavrakis, Elisa Oricchio, Adolfo A. Ferrando, Kim De Keersmaecker, Teresa Palomero, Franki Speleman, Pieter Van Vlierberghe
Abstract: The present invention relates to siRNA hydrogel and a method for manufacturing the same, and more particularly, to siRNA hydrogel for targeted gene silencing, which is nano-structured for targeted gene silencing, and a method for manufacturing the same.
Type:
Grant
Filed:
November 3, 2011
Date of Patent:
April 11, 2017
Assignee:
KAIST IP CO., LTD.
Inventors:
Cheol Am Hong, Yoon Sung Nam, Haeshin Lee
Abstract: ATM kinase is shown to regulate proteasome-mediated protein turnover through suppression of the expression of the ubiquitin-like protein ISG15 (Interferon Stimulated Gene 15). Silencing of the ISG15 pathway restored both the ubiquitin and autophagy pathways, and the UV-mediated degradation of their substrates in A-T cells. The ATM kinase negatively regulates the ISG15 pathway, and the constitutively elevated ISG15 pathway induces proteinopathy in A-T cells, and in A-T patients. These findings indicate that proteasome-mediated protein degradation is impaired in A-T cells due to elevated expression of the ISG15 conjugation pathway, which contributes to progressive neurodegeneration in A-T patients. The ISG15 pathway is a new target for both detection and treatment of A-T Inhibitors if ISG15 expression can be used to inhibit or attenuate neurodegeneration in A-T patients.
Type:
Grant
Filed:
November 29, 2012
Date of Patent:
March 21, 2017
Assignee:
Board of Supervisors of Louisiana State University And Agricultural and Mechanical College
Abstract: The present invention relates to methods of identifying oligonucleotides capable of modulating the immune system in a mammalian subject, comprising analysis of which tertiary structural type said oligonucleotide adopts, in phosphate-buffered saline solution. Further, the invention provides oligonucleotides identifiable by the methods of the invention and to their use in methods of treating diseases, such as inflammatory diseases, autoimmune diseases, infectious diseases, neurodegenerative diseases and cancer.
Type:
Grant
Filed:
August 31, 2015
Date of Patent:
March 14, 2017
Assignee:
INDEX PHARMACEUTICALS AB
Inventors:
Arezou Zargari, Nicolai Kouznetzov, Charlotte Admyre, Petra Von Stein, Oliver Von Stein
Abstract: Provided are methods, compounds, and compositions for reducing expression of ApoCIII mRNA and protein for treating, preventing, delaying, or ameliorating Fredrickson Type I dyslipidemia/FCS/LPLD, in a patient. Such methods, compounds, and compositions increase HDL levels and/or improving the ratio of TG to HDL and reducing plasma lipids and plasma glucose in the patient, and are useful to treat, prevent, delay, or ameliorate any one or more of pancreatitis, cardiovascular disease, metabolic disorder, and associated symptoms.
Type:
Grant
Filed:
February 14, 2014
Date of Patent:
March 14, 2017
Assignee:
Ionis Pharmaceuticals, Inc.
Inventors:
Veronica J. Alexander, Nicholas J. Viney, Joseph L. Witztum
Abstract: Described herein are compositions and methods for the inhibition of miR-122 activity. The compositions have certain nucleoside modifications that yield potent inhibitors of miR-122 activity. The compounds may comprise conjugates to facilitate delivery to the liver. The compositions may be administered to subjects infected with hepatitis C virus, as a treatment for hepatitis C virus and related conditions.
Abstract: Certain embodiments are directed to compounds and compositions targeted to human androgen receptor (AR) for inhibiting androgen receptor levels in a cell, which can be useful for methods of treating cancer and inhibiting cancer cell growth or proliferation.
Type:
Grant
Filed:
September 15, 2015
Date of Patent:
February 14, 2017
Assignee:
Ionis Pharmaceuticals, Inc.
Inventors:
Robert A. Macleod, Youngsoo Kim, Tianyuan Zhou, Susan M. Freier, Punit Seth, Eric Swayze, Brett Monia
Abstract: The present invention provides, among other things, oligonucleotide modulators of human 5?-HT2C receptor (HTR2C) and improved methods and composition for treating HTR2C-related diseases, disorders or conditions based on such modulators. In particular, oligonucleotides modulators according to the invention target specific regions in the Exon V/Intron V junction of the human HTR2C pre-mRNA and drive expression of HTR2C Vb splice isoform, leading to increased generation of non-edited strong HTR2C receptor and enhanced serotonin receptor activity.
Type:
Grant
Filed:
November 9, 2012
Date of Patent:
February 14, 2017
Assignees:
Shire Human Genetic Therapies, Inc., University of Kentucky
Inventors:
Stefan Stamm, Manli Shen, Serene Josiah
Abstract: Provided are methods and compositions for modulating the differentiation of a myeloid derived suppressor cell (MDSC). In particular, described herein are miR-142 polynucleotides and miR-223 polynucleotides that can be used to modulate differentiation of MDSCs. Increased differentiation of a MDSC population, or cells within an MDSC population, can be achieved by increasing the miR-142 and/or miR-223 polynucleotides in a MDSC.
Type:
Grant
Filed:
December 3, 2012
Date of Patent:
January 24, 2017
Assignee:
University of South Florida
Inventors:
Shyam S. Mohapatra, Srinivas Nagaraj Bharadwaj, Subhra Mohapatra
Abstract: The present invention provides methods for tumor treatment by administering an inhibitor of quiescin sulfhydryl oxidase 1 (QSOX1), compositions comprising such inhibitors, and methods for identifying such inhibitors.
Type:
Grant
Filed:
November 6, 2015
Date of Patent:
January 17, 2017
Assignee:
ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY
Abstract: Methods and compositions are provided for treating HIV infection and for inhibiting HIV infection, and for identifying purinergic receptor antagonists or Panx 1 hemi-channel blockers useful therefor. The invention provides a method of treating a mammalian subject having an HIV infection, or suspected of having been exposed to HIV, comprising administering to the mammalian subject an amount of (i) an antagonist of a Panx 1 hemichannel, or (ii) of an inhibitor of a purinergic receptor, effective to inhibit (a) HIV fusion with a target cell, or (b) HIV replication, or (c) HIV entry into a target cell, or two or more of (a), (b) and (c).
Type:
Grant
Filed:
February 28, 2013
Date of Patent:
January 10, 2017
Assignee:
Albert Einstein College of Medicine, Inc.
Abstract: The invention provides a single-stranded nucleic acid molecule containing an expression inhibitory sequence that inhibits expression of a target gene, region (X), linker region (Lx), and region (Xc), wherein the linker region (Lx) is linked between the region (Xc) and the region (Xc), the region (Xc) is complementary to the region (X), at least one of the region (X) and the region (Xc) contains the expression inhibitory sequence, and the linker region (Lx) contains an atomic group derived from an amino acid. The single-stranded nucleic acid molecule can inhibit expression of the target gene.
Abstract: The present invention is directed to RNA interference (RNAi) molecules targeted against a Huntington's disease nucleic acid sequence, and methods of using these RNAi molecules to treat Huntington's disease.
Type:
Grant
Filed:
May 20, 2015
Date of Patent:
December 20, 2016
Assignee:
University of Iowa Research Foundation
Inventors:
Beverly L. Davidson, Alejandro Mas Monteys
Abstract: The present invention provides an alpha-methylacyl-CoA racemase binding aptamers. The present invention further provides a kit for detecting alpha-methylacyl-CoA racemase or cancer in a sample, which comprises the above-mentioned alpha-methylacyl-CoA racemase binding aptamers.
Type:
Grant
Filed:
June 17, 2015
Date of Patent:
December 13, 2016
Assignee:
National Taiwan University
Inventors:
Lin-Chi Chen, Deng-Kai Yang, Chun-Hua Hsu, Ming-Ying Lee
Abstract: Improved compositions and methods for treating muscular dystrophy by administering antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping are described.
Abstract: The present invention discloses multiple treatment regimens for vascular-related diseases and disorders. The present invention provides for methods of treating vascular-related disorders based on gene expression studies from samples collected from individuals having symptoms of vascular-related disorders. Additionally, methods are disclosed involving diagnostic techniques to focus treatment regimens. Finally, methods of treating vascular-related disorder involving targeting microRNAs are also disclosed.
Abstract: A method of ex-vivo increasing insulin content in beta cells or stem cells is disclosed. The method comprising contacting the beta cells or stem cells with an agent for downregulating an activity or expression of miR-7, thereby increasing the insulin content in the beta cells or stem cells.
Abstract: The present invention relates to novel compositions and therapeutic methods for the treatment of cancer, in particular malignant glioma. The compositions include antisense oligonucleotides or RNAs or vectors encoding them which reduce expression of downregulated in renal cell carcinoma (DRR) in tumor cells, and inhibit malignant glioma cell invasion.
Type:
Grant
Filed:
May 22, 2014
Date of Patent:
November 15, 2016
Assignee:
THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY
Inventors:
Kevin Petrecca, Masad Damha, Glen Deleavey